Adalimumab Maintenance Treatment in Ulcerative Colitis: Outcomes by Prior Anti-TNF Use and Efficacy of Dose Escalation

Dose Escalation and Healthcare Resource Use among Ulcerative Colitis Patients Treated with Adalimumab in English Hospitals: An Analysis of Real-World Data

(2016) Christopher M. Black et al.   PLoS One

Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed

(2015) J. P. Gisbert et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Infliximab Dose Escalation as an Effective Strategy for Managing Secondary Loss of Response in Ulcerative Colitis

(2015) Carlos Taxonera et al.   DIGESTIVE DISEASES AND SCIENCES

Tu1370 Efficacy of Adalimumab (ADA) Therapy in Patients With Steroid-Dependent Ulcerative Colitis (UC)

(2015) Manuel Barreiro-de Acosta et al.   GASTROENTEROLOGY

Efficacy and Safety of Adalimumab in Ulcerative Colitis Refractory to Conventional Therapy in Routine Clinical Practice

(2015) Anita Bálint et al.   Journal of Crohns & Colitis

Prior response to infliximab and early serum drug concentrations predict effects of adalimumab in ulcerative colitis

(2014) F. Baert et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Four-Year Maintenance Treatment With Adalimumab in Patients with Moderately to Severely Active Ulcerative Colitis: Data from ULTRA 1, 2 and 3

(2014) Jean-Frederic Colombel et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Development of an Algorithm Incorporating Pharmacokinetics of Adalimumab in Inflammatory Bowel Diseases

(2014) Xavier Roblin et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Associations between functional polymorphisms in the NFκB signaling pathway and response to anti-TNF treatment in Danish patients with inflammatory bowel disease

(2014) S Bank et al.   PHARMACOGENOMICS JOURNAL

Adalimumab in active ulcerative colitis: A “real-life” observational study

(2013) Alessandro Armuzzi et al.   DIGESTIVE AND LIVER DISEASE

One-year maintenance outcomes among patients with moderately-to-severely active ulcerative colitis who responded to induction therapy with adalimumab: subgroup analyses from ULTRA 2

(2012) W. J. Sandborn et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Observational study on the efficacy of adalimumab for the treatment of ulcerative colitis and predictors of outcome

(2012) Orlando García-Bosch et al.   Journal of Crohns & Colitis

Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis

(2011) William J. Sandborn et al.   GASTROENTEROLOGY

Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial

(2011) W. Reinisch et al.   GUT

Adalimumab induction and maintenance therapy for patients with ulcerative colitis previously treated with infliximab

(2010) C. Taxonera et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS